NIH opportunity – Genomics of HIV/AIDS Drug Response and Co-Morbidities (R01)

September 27, 2016 by School of Medicine Webmaster

This FOA will expand the use of high-throughput genotyping, genomic sequencing, and related genomic technologies, and will generate widely available data resources for research use, to improve the efficacy and the safety and ease of use of HIV/AIDS therapies and of non-HIV drugs used to treat HIV/AIDS patients, and to reduce HIV/AIDS-related comorbidities, co-infections, and complications. It will also support analysis of existing genomic data for these purposes and deposition of analysis results into appropriate data resources to enhance their value.

Specific Areas of Research Interest

This FOA centers on addressing research gaps related to the use of high-throughput genotyping, genomic sequencing, and related genomic technologies in identifying host genetic predictors of response, both efficacy and safety, to HIV/AIDS therapies, adverse reactions to non-HIV therapies in HIV/AIDS patients (including but not limited to severe cutaneous adverse reactions, hepatotoxicity, renal toxicity, immune reconstitution inflammatory syndrome, lipodystrophy, dyslipidemia, CNS toxicity, sleep disturbance, metabolic and gastrointestinal distress, peripheral neuropathy, and osteonecrosis), and predictors of AIDS-related comorbidities.

NHGRI encourages applications that address how genomic information may contribute to the reduction of health disparities and applications that include population groups traditionally under-represented in genomic research. PD(s)/PI(s) are also encouraged to include investigators and trainees from diverse backgrounds who are underrepresented in genomic research.

The following are examples of the types of research studies that would be appropriate for this FOA. This list is provided as a set of examples, and should not be considered exhaustive. Applicants are encouraged to propose creative and innovative research topics and approaches that go beyond the specific examples listed here:

  • Identifying genomic correlates of drug efficacy, toxicity and co-morbidity using dense SNP genotyping and/or targeted or whole exome/genome sequencing data in HIV/AIDS patients, and, as appropriate, a limited number of control patients not available through accessible databases;
  • Developing, refining, and/or validating standardized drug efficacy, toxicity and co-morbidity phenotypes in well-characterized HIV/AIDS patients;
  • Characterizing validated drug efficacy, toxicity and co-morbidity phenotypes in existing HIV/AIDS cohorts and clinical trial populations and relating them to available dense SNP genotyping or genomic sequencing data;
  • Preparing genomic and phenotyping data for analysis and deposition for research access, by imputing genotyping data against appropriate reference populations, assigning phenotypes, correlating genetic variants with phenotypes, and other analytic processes as appropriate;
  • Developing protocols for prospective collection of efficacy, toxicity and co-morbidity data in ancestrally diverse or minimally characterized cohorts available nationally and internationally.

Deadlines:  standard dates apply


Filed Under: Funding Opportunities